PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 59 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,853 | -4.1% | 1,818 | +32.4% | 0.00% | 0.0% |
| Q2 2023 | $19,661 | +100.6% | 1,373 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $9,803 | -37.7% | 1,373 | -2.1% | 0.00% | 0.0% |
| Q4 2022 | $15,730 | +1.3% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $15,534 | +31.3% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $11,833 | -38.0% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $19,081 | -83.7% | 1,402 | -76.4% | 0.00% | -50.0% |
| Q4 2021 | $116,879 | -38.7% | 5,942 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $190,738 | -5.2% | 5,942 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $201,137 | +49.3% | 5,942 | +65.7% | 0.00% | +50.0% |
| Q1 2021 | $134,728 | +13.1% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $119,160 | -9.4% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $131,535 | +11.4% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $118,048 | +27.5% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $92,616 | – | 3,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |